Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China
Annals of Clinical and Translational Neurology · 2024-08 · 11 (8) · 2212-2221
DOI: 10.1002/acn3.52142 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 07.07.2024. Verfasst von Sushan Luo und 22 weiteren Autor:innen. Beteiligte Einrichtung: Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fuda…. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Plan of China.
Abstract (Originalsprache)
Objective
Efgartigimod, a neonatal Fc receptor antagonist, facilitates antibody degradation including pathogenic IgGs. The ADAPT study demonstrated the tolerability and efficacy of efgartigimod in the treatment of generalized myasthenia gravis (gMG). However, very limited evidence is available for the Chinese population, and it remains inconclusive about which kind of patients are selected to preferentially receive efgartigimod in real‐world settings.
Methods
This multicenter cohort study included gMG patients treated at 14 neuromuscular reference centers in China. The Myasthenia Gravis Activities of Daily Living (MG‐ADL) score, immunosuppressants, and the incidence of treatment‐emergent adverse events (TEAEs) were prospectively collected.
Results
Of the 1640 gMG admitted between September and December 2023, 61 (3.7%) received efgartigimod for at least one treatment cycle. Among them, 56 cases (92%) were anti‐AChR antibody‐positive, 4 were anti‐MuSK antibody‐positive, and 1 was seronegative. Thymoma‐associated myasthenia gravis accounted for most cases (44%, 27 out of 61). The principal causes of efgartigimod initiation included MG acute exacerbation (MGAE) (48%, 29 out of 61) and myasthenic crisis (MC) (15%, 9 out of 61). Clinically meaningful improvement was rapidly achieved in 97% (58 out of 61) of patients at 1.3 ± 0.7 weeks. By week 12, the MG‐ADL score reduced to 3.8 ± 4.1 (baseline:10.5 ± 5.2) for all participants, while it reduced to 4.0 ± 4.7 for MGAE and 3.8 ± 4.2 for MC, respectively. All but one TMG patient required no additional rescue therapies after efgartigimod initiation. 11.5% (7 out of 61) reported ≥1 TEAEs.
Interpretation
This multicenter cohort study demonstrated the efficacy of efgartigimod in rapid control of gMG. Patients with MGAE or MC would benefit from efgartigimod treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, 200040, China.
- Department of Myopathy, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
- Department of Neurology, Hongkong University Shenzhen Hospital, Shenzhen, 518053, China.
- Department of Neurology, Qilu Hospital of Shandong University, Jinan, 250012, China.
- Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
- Department of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
ORCID-Profile: Sushan Luo, Qilong Jiang, Zhangyu Zou, Daojun Hong, Song Tan, Zhouao Zhang, Yong Zhang, Xiuming Guo, Jianquan Shi, Jianying Xi, Chongbo Zhao
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Plan of China
Zitieren
APA
Luo, S., Jiang, Q., Zeng, W., Wang, Q., Zou, Z., Yu, Y., Hong, D., Zeng, Q., Tan, S., Zhang, Z., Zhang, Y., Guo, X., Chen, J., Zhao, Z., Huang, S., Shi, J., Chen, Y., Du, L., Yan, C., …, & Chinese Myasthenia Gravis Collaborating Group (CMGCG) (2024). Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China. Annals of Clinical and Translational Neurology, 11(8), 2212-2221. https://doi.org/10.1002/acn3.52142
Vancouver
Luo S, Jiang Q, Zeng W, Wang Q, Zou Z, Yu Y, et al. Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China. Annals of Clinical and Translational Neurology. 2024;11(8):2212-2221. doi:10.1002/acn3.52142
BibTeX
@article{Luo2024,
author = {Luo, Sushan and Jiang, Qilong and Zeng, Wenshuang and Wang, Qinzhou and Zou, Zhangyu and Yu, Yanyan and Hong, Daojun and Zeng, Quantao and Tan, Song and Zhang, Zhouao and Zhang, Yong and Guo, Xiuming and Chen, Jing and Zhao, Zhongyan and Huang, Shixiong and Shi, Jianquan and Chen, Ying and Du, Lei and Yan, Chong and Xi, Jianying and Song, Jie and Zhao, Chongbo and Chinese Myasthenia Gravis Collaborating Group (CMGCG), Chinese Myasthenia Gravis Collaborating Group (CMGCG)},
title = {Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
volume = {11},
number = {8},
pages = {2212--2221},
doi = {10.1002/acn3.52142}
}
EUVIMED